Valuation: Lundbeck

Market Cap 40.88B 6.25B 5.47B 5.04B 4.66B 8.84B 596B 8.99B 60.27B 23.67B 294B 23.48B 22.97B 1,010B P/E 2026 *
9.31x
P/E 2027 * 9.18x
Enterprise Value 44.97B 6.88B 6.02B 5.55B 5.13B 9.72B 656B 9.89B 66.3B 26.04B 323B 25.82B 25.26B 1,111B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.58x
Free-Float
30.76%
Yield 2026 *
3.53%
Yield 2027 * 3.64%
1 day-0.55%
1 week-2.04%
Current month-1.64%
1 month-1.50%
3 months+5.73%
6 months-6.86%
Current year-0.55%
1 week 35.9
Extreme 35.9
37.45
1 month 35.65
Extreme 35.65
37.75
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-2.04% - - 6.25B
+1.66%+2.50%+13.58%+97.17% 94.36B
+0.87%-1.31%+46.49%+152.00% 55.23B
+3.55%+3.55%+3.91%+269.62% 22.56B
+0.37%+0.06%-15.11%-23.30% 8.01B
+1.98%-2.23%-26.79%-34.74% 7.6B
+0.72%-2.26%-11.96%-27.99% 6.66B
-0.09%+0.76%-2.59%+22.73% 5.36B
+0.20%+1.42%-6.18%-7.01% 3.68B
+0.95%-1.46%+10.88%+16.56% 3.34B
Average +1.04%-0.44%+1.36%+51.67% 22.98B
Weighted average by Cap. +1.62%+0.69%+17.08%+111.99%

Financials

2026 *2027 *
Net sales 25.77B 3.94B 3.45B 3.18B 2.94B 5.57B 376B 5.67B 38B 14.92B 185B 14.8B 14.48B 637B 25.88B 3.96B 3.46B 3.19B 2.95B 5.6B 378B 5.69B 38.16B 14.98B 186B 14.86B 14.54B 639B
Net income 4.55B 696M 609M 562M 519M 985M 66.42B 1B 6.71B 2.64B 32.72B 2.61B 2.56B 112B 4.6B 703M 615M 567M 524M 994M 67.06B 1.01B 6.78B 2.66B 33.03B 2.64B 2.58B 114B
Net Debt 4.09B 625M 547M 505M 466M 884M 59.65B 899M 6.03B 2.37B 29.39B 2.35B 2.3B 101B -93.58M -14.31M -12.52M -11.55M -10.67M -20.24M -1.37B -20.58M -138M -54.18M -672M -53.74M -52.57M -2.31B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
13/07/26 DKK 36.00 -0.83% 28,178
10/07/26 DKK 36.30 0.00% 70,570
09/07/26 DKK 36.30 -1.09% 88,750
08/07/26 DKK 36.70 -0.14% 55,384
07/07/26 DKK 36.75 0.00% 99,517
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.48DKK
Average target price
47.62DKK
Spread / Average Target
+12.11%

Quarterly revenue - Rate of surprise